“CUV have treated one stroke patient. It will take another five years for the trials and approval process. The realistic chances of success are only 5-10%.”
Wolgen has already said they will try to use the data from PASS and other sources to bolster an application for Prenumbra. After all it is afamelanotide. Five years seems outlandish, they are slated to finish the program in 2023, two years from now. And if it works, likely with a breakthrough designation.
- Forums
- ASX - By Stock
- CUV
- Revenue EXPLOSION Coming?
Revenue EXPLOSION Coming?, page-47
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CUV (ASX) to my watchlist
|
|||||
Last
$14.47 |
Change
-0.085(0.58%) |
Mkt cap ! $725.1M |
Open | High | Low | Value | Volume |
$14.60 | $14.60 | $14.32 | $359.6K | 24.84K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 750 | $14.46 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.47 | 71 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 193 | 14.450 |
8 | 208 | 14.440 |
6 | 204 | 14.430 |
4 | 379 | 14.420 |
3 | 134 | 14.410 |
Price($) | Vol. | No. |
---|---|---|
14.470 | 175 | 7 |
14.480 | 36 | 1 |
14.490 | 50 | 2 |
14.500 | 55 | 3 |
14.510 | 139 | 2 |
Last trade - 13.13pm 10/09/2024 (20 minute delay) ? |
Featured News
CUV (ASX) Chart |